Correlation Between Inhibikase Therapeutics and SAB Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and SAB Biotherapeutics, you can compare the effects of market volatilities on Inhibikase Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and SAB Biotherapeutics.
Diversification Opportunities for Inhibikase Therapeutics and SAB Biotherapeutics
0.62 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Inhibikase and SAB is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and SAB Biotherapeutics go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and SAB Biotherapeutics
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 0.86 times more return on investment than SAB Biotherapeutics. However, Inhibikase Therapeutics is 1.16 times less risky than SAB Biotherapeutics. It trades about 0.09 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about 0.04 per unit of risk. If you would invest 182.00 in Inhibikase Therapeutics on September 2, 2024 and sell it today you would earn a total of 110.00 from holding Inhibikase Therapeutics or generate 60.44% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. SAB Biotherapeutics
Performance |
| Timeline |
| Inhibikase Therapeutics |
| SAB Biotherapeutics |
Inhibikase Therapeutics and SAB Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and SAB Biotherapeutics
The main advantage of trading using opposite Inhibikase Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| SAB Biotherapeutics vs. Tff Pharmaceuticals | SAB Biotherapeutics vs. Eliem Therapeutics | SAB Biotherapeutics vs. Inhibrx | SAB Biotherapeutics vs. Enliven Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Complementary Tools
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |